|View printer-friendly version|
|August 16, 2002 4:18 p.m.|
|Teva Comments on Court Affirmation of Relafen® Patent Challenge|
Jerusalem, Israel, August 16, 2002 - Israel Makov, CEO of Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) said today: "We are very pleased that the U.S. Federal Circuit Court of Appeals, yesterday, affirmed the decision of the Federal District Court of Massachusetts in our successful challenge of GlaxoSmithKline's patent position relating to Nabumetone. While we have all along been confident that our position was a strong one, yesterday's Court of Appeals decision further reinforces our strategy to challenge improperly granted patents that limit our ability to provide low cost pharmaceutical products to the U.S. market."